ORBIMED ADVISORS LLC 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-21 4:11 pm Unchanged | 2024-02-16 | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.100% | 0 (Unchanged) | Filing |
| 2023-11-17 08:27 am Unchanged | 2023-11-17 | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.000% | 0 (Unchanged) | Filing |
| 2023-11-14 4:57 pm Unchanged | 2023-11-13 | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.000% | 0 (Unchanged) | Filing |
| 2023-05-08 5:01 pm Purchase | 2023-05-04 | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.200% | 1,460,932 (+23.95%) | Filing |
| 2023-05-02 7:28 pm Purchase | 2023-04-28 | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 6,098,797 13.100% | 1,405,168 (+29.94%) | Filing |
| 2023-02-23 3:23 pm Purchase | 2023-02-17 | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 4,693,629 10.600% | 1,295,700 (+38.13%) | Filing |